Pennington Biomedical Research Center

SALT LAKE CITY, Oct. 2, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will host a virtual key opinion leader (KOL) event on LPCN 2401 for improved body composition in obesity management on Wednesday, October 16, 2024 at 11:00 am ET. To register, click here. The event will feature Frank Greenway, MD (Professor and Chief Medical Officer at Pennington Biomedical Research Center), who will discuss the unmet needs and current treatment landscape in obesity management with a focus on fat loss and lean muscle mass preservation for patients on incretin therapies. The event will also review positive data from the Phase 2 study of LPCN 2401, comprised of an oral proprietary androgen receptor agonist, which showed significant improvements in body composition. The data support the potential for LPCN 2401 to be used as an adjunct with incretin mimetics (GLP-1/GIP agonists) or as a monotherapy, including post incretin mimetic discontinuation. A live question and answer session will follow the formal presentation. About LPCN 2401 LPCN 2401 is an oral formulation comprised of a proprietary anabolic androgen receptor agonist targeted for once daily regimen. Data from preclinical and clinical studies support the potential of LPCN 2401 in preserving lean mass while reducing fat mass (preferentially VAT and android fat) and beneficial liver and bone health effects. As adjunct therapy to incretin mimetics, LPCN 2401 has potential to amplify GLP-1 action, ameliorate loss of muscle mass, improve muscle quality and functionality, and amplify fat mass loss with improved body composition, with no overlapping GI side effects. Moreover, post incretin mimetic discontinuation, LPCN 2401 has potential to attenuate weight gain, prevent "fat overshoot," and accelerate lean mass rebound. About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression; LPCN 2101, for the potential treatment of epilepsy; LPCN 2203, an oral candidate targeted for the management of essential tremor; LPCN 2401, comprised of an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics as an aid for improved body composition in chronic weight management; and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for chronic weight management, LPCN 1148 for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit . Forward-Looking Statements This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at . Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law. SOURCE Lipocine Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TUESDAY, June 18, 2024 -- Combining antiobesity medications enhances preoperative weight loss in individuals with high body mass index (BMI) preparing for metabolic surgery , according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego. Michael Kachmar, D.O., from the Pennington Biomedical Research Center in Baton Rouge, Louisiana, and colleagues characterized the success of preoperative weight-loss therapy among patients with high BMI (≥70 kg/m 2 ) preparing for metabolic surgery. The analysis included 113 patients. The researchers found that length of treatment ranged from 2.7 to 364 weeks, with an average time of 72.9 days. For nonpharmacologic medically supervised weight loss, the mean percent total body weight loss (%TBWL) was 5.95 percent; %TBWL was 8.14 percent for mono-glucagon-like peptide 1 and 13.1 percent for multimodal antiobesity medication. Mean absolute BMI reductions were 7.36, 7.51, and 9.61 kg/m 2 , respectively. Both %TBWL and absolute BMI reduction were highest for those treated with multimodal antiobesity medication therapy for 23 to 51 weeks. "Combining antiobesity medications may achieve much greater presurgery weight loss than other methods for those with extreme obesity," coauthor Phil Schauer, M.D., also from Pennington Biomedical, said in a statement. "Many patients who would otherwise be considered 'too sick for surgery' may now qualify." Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

FRIDAY, June 14, 2024 -- Taking a cutting-edge weight-loss drug could help extremely obese patients drop enough pounds to be eligible for bariatric surgery, a new study shows. Patients with extreme obesity -- a BMI of 70 or more -- are at higher risk of complications from surgery compared to people who weigh less. Weight loss prior to surgery can lower that risk, but up to now nothing’s been able to help patients lose enough weight to make a difference, researchers say. However, new GLP-1 agonist medications like Ozempic , Wegovy and Zepbound have been shown to help people quickly shed pounds. For this trial, researchers recruited 113 extremely obese patients and assigned them to either a single GLP-1 drug, more than one GLP-1 drug or a medically supervised diet and exercise program. Patients were treated an average of 73 days. People on multiple drugs had the greatest weight loss, dropping about 13% of their total body weight. A single GLP-1 drug helped people lose a little more than 8% of their body weight, while diet and exercise helped participants drop about 6% of their body weight. The findings were presented Thursday at the American Society for Metabolic and Bariatric Surgery’s annual meeting in San Diego. “Combining anti-obesity medications may achieve much greater pre-surgery weight loss than other methods for those with extreme obesity,” said researcher Dr. Phil Schauer , director of the Metamor Metabolic Institute at Pennington Biomedical in Baton Rouge, La. “Many patients who would otherwise be considered ‘too sick for surgery’ may now qualify.” More than 42% of Americans are obese, researchers said in background notes. GLP-1 drugs work by mimicking a hormone in the body that controls insulin release and acts to reduce hunger and delay stomach emptying. “More studies are needed to determine the optimal role of GLP-1s before and after metabolic and bariatric surgery among different patient groups,” Dr. Marina Kurian , president of the American Society for Metabolic and Bariatric Surgery, said in a meeting news release. “Obesity must be viewed like other chronic diseases, where sometimes more than one therapy is necessary over time and for different reasons,” added Kurian, who was not involved in the study. Because this research was presented at a medical meeting, it should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.